Clinical trials: Ejection Fraction
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
The recent study is planned to investigate the impact of Ertugliflozin on total burden of ventricular arrhythmias. Further objectives will be number of therapeutic interventions of implanted devices, atrial fibrillation, heart…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy
- Trial name
- ERASE (NCT04600921)
- Testing
- Ertugliflozin 5 mg
- Where
- 8 sites in Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Heart Disease, Heart Failure With Preserved Ejection Fraction
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that has no proven effective treatment. This study assessed the effects of acute nitrite administration on resting and exercise hemodynamics…
- Conditions
- Heart Disease, Heart Failure With Preserved Ejection Fraction, Exercise Intolerance, Pulmonary Hypertension
- Trial name
- NCT01932606
- Testing
- Nitrite
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Barry Borlaug
Heart Failure
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
- Trial name
- NCT03611153
- Testing
- AZD4831 Oral Myeloperoxidase Inhibitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Heart Failure
Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction
This study will look at how pacing your heart may assist your daily activities and how you are feeling.
- Trial name
- RESET (NCT00670111)
- Testing
- Insignia Plus / Ultra (Guidant/Boston Scientific)
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Boston Scientific Corporation
Cardiac Pacing, Right Ventricular Pacing
Optimize RV Follow-up Selective Site Pacing Clinical Trial
The purpose of the Optimize RV Follow-Up study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed.
- Conditions
- Cardiac Pacing, Right Ventricular Pacing, Left Ventricular Ejection Fraction
- Trial name
- ORVFUP (NCT00949715)
- Testing
- Medtronic or Vitatron Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
- Where
- 12 sites in United States, Israel and 1 more
- Volunteers
- 67 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Preserved Ejection Fraction
Dapagliflozin (DAPA) Effects in HFpEF
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and…
- Trial name
- NCT04730947
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Heart Failure
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries.
- Trial name
- SATELLITE (NCT03756285)
- Testing
- AZD4831
- Where
- 13 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary…
- Trial name
- NCT00684021
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center, Houston
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
HIV/AIDS, Heart Failure With Preserved Ejection Fraction
The ENCHANTMENT HIV Study
Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal…
- Trial name
- NCT04153136
- Testing
- Sacubitril-Valsartan 49-51Mg Oral Tablet
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary…
- Trial name
- OUTSTEP-HF (NCT02900378)
- Testing
- LCZ696 (Sacubitril/Valsartan), Enalapril
- Where
- 119 sites in Belgium, Bulgaria and 17 more
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Diastolic Heart Failure, Hypertensive Heart Disease
Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Heart failure with preserved systolic function (HF-PSF, or 'diastolic heart failure') accounts for half of hospitalizations for heart failure in patients over the age of 65.
- Trial name
- DASH-DHF (NCT00939640)
- Testing
- DASH/sodium-restricted diet (SRD)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Heart Failure
Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that has no proven effective treatment. This study will assess the effects of nebulized inhaled nitrite administration on resting and…
- Trial name
- NCT02262078
- Testing
- Sodium Nitrite Inhalation Solution
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Healthy
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying.
- Trial name
- NCT00685477
- Testing
- Experimental Sequence ABC, Experimental Sequence ACB, Experimental Sequence BAC
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Temple University
Cardiac Disease
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as…
- Trial name
- BENEFIT2 (NCT03719612)
- Testing
- DEFINITY®
- Where
- 15 sites in United States
- Volunteers
- 160 people
- Sponsor
- Lantheus Medical Imaging